JAZZ Jazz Pharmaceuticals PLC - 8-K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election. Consistent with the Company’s commitment to ongoing board refreshment and board effectiveness, the Board will continue to evaluate its composition and to facilitate orderly board succession processes. Ms. O’Riordan’s decision was not the result of any dispute or disagreement with the Company or the Company’s Board on any matter relating to the operations, policies or practices of the Company.